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Abstract: A novel gold(III) complex, [AuCl2{(S,S)-Et2eddl}]PF6, ((S,S)-Et2eddl = O,O′-diethyl
ester of ethylenediamine-N,N′-di-2-(4-methyl)pentanoic acid) was synthesized and characterized
by IR, 1D (1H and 13C), and 2D (H,H-COSY and H,H-NOESY) NMR spectroscopy, mass
spectrometry, and elemental analysis. Density functional theory calculations confirmed that
(R,R)-N,N′ diastereoisomer was energetically the most stable isomer. In vitro antitumor action of
ligand precursor [(S,S)-H2Et2eddl]Cl2 and corresponding gold(III) complex was determined against
tumor cell lines: human adenocarcinoma (HeLa), human colon carcinoma (LS174), human breast
cancer (MCF7), non-small cell lung carcinoma cell line (A549), and non-cancerous cell line human
embryonic lung fibroblast (MRC-5) using microculture tetrazolium test (MTT) assay. The results
indicate that both ligand precursor and gold(III) complex have showed very good to moderate
cytotoxic activity against all tested malignant cell lines. The highest activity was expressed by
[AuCl2{(S,S)-Et2eddl}]PF6 against the LS174 cells, with IC50 value of 7.4 ± 1.2 µM.
Keywords: gold(III) complex; R2edda-type ligand; DFT; cytotoxicity
1. Introduction
Cancer is a disease in which a group of cells display uncontrolled growth, invasion, and sometimes
metastasis [1]. Over the last fifty years, about 500,000 natural and synthetic chemical compounds have
been tested for their anticancer activity, but only about 25 of these are in wide use today [2]. In particular,
transition metal complexes offer potential advantages over the more common organic-based drugs.
Cisplatin has been proven through many years of successful implementation in the treatment of
various types of cancers, such as ovarian, cervical, bladder, lung, head, and neck [3–10]. Despite the
therapeutic success of cisplatin, severe toxicities, including oto-, nephro-, and neurotoxicity, its narrow
spectrum of activity and low water solubility limit its clinical utility [11,12]. Therefore, great efforts
have been made to develop new derivatives with improved pharmacological properties, and cisplatin
has become the prototype of a unique class of antineoplastic agents [10].
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Several families of non-platinum metal complexes have been studied extensively as potential
cytotoxic and antitumor agents [13–16]. In the last 10–20 years, a number of gold(III) complexes
that are highly cytotoxic towards cancer cells have been discovered [17,18]. Gold(III) complexes
show chemical features that are very close to those of clinically employed platinum(II) complexes,
such as the preference for square-planar geometry and d8 electronic configuration [19,20]. However,
in comparison with platinum(II) compounds, gold(III) analogues turned out to be relatively unstable
and light-sensitive with high redox potential, making their use rather problematic under physiological
conditions [21].
Gold(III) complexes differ significantly and are especially susceptible to reduction to gold(I) and
colloidal gold [22]. Chemical strategies for imparting redox stability to gold(III) complexes typically
involve the use of chelating and macrocyclic ligands containing strong neutral or anionic σ-donor atoms
(C, N, and O to match the hard gold(III) ion). More recent studies have demonstrated that polydentate
ligands (such as polyamines) enhance the stability of gold(III) complexes in biological environments,
and despite the fact gold(III) complexes are often structural analogs of cisplatin, they are widely
thought to impart tumor cell death via a different mechanism [23]. Up to now, very little is known
concerning the molecular mechanisms underlying the pharmacological effects of gold(III)-based
antitumor metallodrugs. Interest in the reactions of some biological N-donor nucleophiles with
gold(III) complexes could be very important because there is evidence of direct interactions of gold(III)
complexes with a different model of proteins [24]. Indeed, it has been shown that the therapeutic effect
of gold therapies may originate within the mitochondria, with cell death possibly being initiated via
the inhibition of the enzyme thioredoxin reductase [24].
Recently, our research group reported the synthesis, characterization, and in vitro
biological evaluation of gold(III) complexes with N,N′-ethylenediamine bidentate ester
ligands [19,20]. In this work, we report the synthesis, characterization, and cytotoxic activity
of novel gold(III) complex, [AuCl2{(S,S)-Et2eddl}]PF6, ((S,S)-Et2eddl = O,O′-diethyl ester of
ethylenediamine-N,N′-di-2-(4-methyl)pentanoic acid). To elucidate the features that determine the
preferred configuration of (S,S)-Et2eddl ligand coordinated to the gold(III) complex, density functional
theory analyses was performed. This newly synthesized complex, together with already-reported
ligand precursor [25], were tested against tumor cell lines: HeLa human adenocarcinoma, human colon
carcinoma (LS174), human breast cancer (MCF7), non-small cell lung carcinoma cell line (A549),
and MRC-5 normal human embryonic lung fibroblast cell line.
2. Experimental
2.1. Materials and Methods
[(S,S)-H2Et2eddl]Cl2 was synthesized according to the method described in [25]. Na[AuCl4] was
synthesized by the standard procedure [26]. Elemental analyses were performed on an Elemental
Vario EL III microanalyzer. A Nicolet 6700 FT–IR spectrometer and ATR (attenuated total reflection)
technique were used for recording mid-infrared spectra (400–4000 cm−1). 1H, 13C, H,H-COSY and
H,H-NOESY NMR spectra were recorded on a Bruker Avance III 500 spectrometer. High resolution
mass spectrum of the complex was recorded with an Orbitrap LTQ XL instrument (Thermo Scientific,
Bremen, Germany) in MeOH. Reagents and solvents were of commercial reagent grade quality and
used without further purification.
2.2. Synthesis of Complex [AuCl2{(S,S)-Et2eddl}]PF6
First, 0.126 mmol (0.053 g) of [(S,S)-H2Et2eddl]Cl2 was suspended in a minimum amount of
MeOH (3 mL), and LiOH·H2O (0.011 g, 0.252 mmol) was added. After 1 h of stirring, deprotonated
ligand dissolved completely. Then, 4 mL of Na[AuCl4]·2H2O (0.050 g, 0.126 mmol) solution in MeOH
was introduced in the flask, followed by addition of solid NH4PF6 (0.062 g, 0.378 mmol). Reaction was
performed in the dark at room temperature. The solution was evaporated under vacuum and the
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yellow product was washed with an excess of water. After filtration, the complex was recrystallized in
MeOH and air-dried.
Yield 57 mg, 59%. Anal. Calcd. for C18H36N2O4AuCl2PF6: C, 28.55; H, 4.79; N, 3.70%. Found:
C, 28.35; H, 4.88; N, 3.65%. 1H NMR (500 MHz, CDCl3): Isomer A: 1.00 (m, C6,7H3, 6H), 1.34 (m,
CH3CH2–OOC–, 6H), 1.75 (m, C5H, 2H), 1.87 (m, C4H2, 4H), 3.61 (m, C1H2, 4H), 4.21 (m, C2H, 2H), 4.34
(m, CH3CH2–OOC–, 4H), 5.21 (s, NH, 2H). Isomer B: 1.00 (m, C6,7H3, 6H), 1.34 (m, CH3CH2–OOC–,
6H), 1.87 (m, C5H, 2H), 1.87(m, C4H2, 4H), 4.02 (m, C1H2, 4H), 4.34 (m, CH3CH2–OOC–, 4H), 4.56
(m, C2H, 2H), 5.15 (s, NH, 2H). 13C NMR (125 MHz, CDCl3): Isomer A: 14.0 (CH3CH2–OOC–),
22.1 (C6,7), 24.9 (C5), 39.0 (C4), 47.9 (C1), 59.8 (C2), 63.1 (CH3CH2–OOC–), 169.9 (C3); Isomer B: 14.0
(CH3CH2–OOC–), 22.4 (C6,7), 23.6 (C5), 38.3 (C4), 44.1 (C1), 59.8 (C2), 63.5 (CH3CH2–OOC–), 170.7
(C3). Isomer ratio: 3/1 (A/B). IR (ATR, cm−1): νmax = 2976, 2875, 1736, 1471, 1241, 1213, 863, 489. HR
ESI–MS (CH3OH), m/z: 611.1688 [M]+.
2.3. Computational Details
Gaussian 09 package was used to perform geometry optimizations [27]. B3LYP functional [28]
was used for structure optimizations, and the Stuttgart/Dresden (SDD) basis set was employed for
all atoms in the calculations [29,30]. Optimizations of all systems were done without symmetry
restrictions. Resulting geometries were characterized as equilibrium structures by analysis of force
constants of normal vibrations.
2.4. Biological Studies
2.4.1. Preparation of Drug Solutions
The solutions of the investigated gold(III) complexes were prepared in DMSO (Sigma-Aldrich,
St. Louis, MO, USA) at a concentration of 1 mM, and diluted by nutrient medium to various working
concentrations. Nutrient medium was RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) supplemented
with 10% fetal bovine serum (FBS; Biochrom AG, Berlin, Germany) and penicillin/streptomycin
(Sigma-Aldrich, St. Louis, MO, USA).
2.4.2. Cell Lines
Cervix adenocarcinoma cell line (HeLa), human colon carcinoma (LS174), human breast cancer
(MCF7), non-small cell lung carcinoma cell line (A549), and a non-cancerous cell line human embryonic
lung fibroblast (MRC-5) were grown in RPMI-1640 medium (Sigma). Media were supplemented with
10% fetal bovine serum, 2 mM L-glutamine, and 1% penicillin–streptomycin (Sigma).
2.4.3. Determination of Cell Survival
Target cells HeLa (2000 cells/well), LS174 (7000 cells/well), MCF7 cells (3000 cells/well), A549
(5000 cells/well), and non-cancerous MRC-5 (5000 cells/well) were seeded into the wells of a 96-well
flat-bottomed microtitre plate. Twenty-four hours later, after the cell adhesion, different concentrations
of investigated compounds were added to the wells, except for the controls, where only the complete
medium was added. The final concentration range used in the experiments was 1–200 µM (12.50, 25,
50, 100, and 200 µM). The final concentration of DMSO never exceeded 0.5%, which is a non-toxic
concentration for the cells. All experiments were performed in technical and biological triplicates.
Culture medium with corresponding concentrations of investigated compounds, but without cells,
was used as blank, also in triplicate. The cultures were incubated for 72 h, and the effects of the
investigated compounds on cancer cell survival were determined using the microculture tetrazolium
test (MTT), according to Mosmann [31] with modification by Ohno and Abe [32], 72 h after the addition
of the investigated compounds. Briefly, 20 µL of MTT solution (5 mg/mL of phosphate-buffered saline,
PBS) was added to each well. Samples were incubated for an additional 4 h at 37 ◦C in a humidified
atmosphere of 5% CO2 (v/v). Afterward, 100 mL of 100 g/L sodium dodecyl sulfate (SDS) were added
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in order to extract the insoluble formazan, which represents the product of the conversion of the MTT
dye by viable cells. The number of viable cells in each well is proportional to the intensity of the
absorbance (A) of light, which was measured in an enzyme-linked immunosorbent assay (ELISA)
plate reader at 570 nm, 24 h later. To determine cell survival (%), the A of a sample with cells grown
in the presence of various concentrations of the investigated compounds was divided by the control
optical density (the A of control cells grown only in nutrient medium) and multiplied by 100. The A of
the blank was always subtracted from the A of the corresponding sample incubated with the target
cells. IC50 is defined as the concentration of an agent inhibiting cell survival by 50% compared with
the vehicle-treated control. Cisplatin was used as positive control. All experiments were performed
in triplicate.
3. Results
3.1. Synthesis and Characterization
In the reaction of Na[AuCl4]·2H2O and an equimolar amount of corresponding ligand (Scheme 1),
previously deprotonated with LiOH, upon precipitation in the presence of PF6− ions, the desired
complex was obtained as a yellow product. The prepared complex is soluble in methanol, ethanol,




















































High‐resolution  electrospray  ionization  mass  spectrometry  (HR  ESI‐MS)  was  recorded  in 
positive ion mode, and the [M−PF6]+ peak was detectable. Additionally, the proposed stoichiometric 
formula  of  synthesized  complex  is  in  agreement  with  elemental  analysis.  The  IR  spectra  of 
synthesized complex show the characteristic absorption for aliphatic esters COOR strong absorption 
stretching  band  ν(C=O)  at  1736  cm−1,  similarly  to  the  ligand  precursor  [(S,S)‐H2Et2eddl]Cl2  [25], 
indicating  that  coordination  of  the  carbonyl  oxygen  atom  to  the  metal  center  is  excluded. 
Additionally, a band arising from ν(C–O) was found at 1241 cm−1. Asymmetric ν(CH3), ν(CH2), and 
ν(CH)  stretching vibrations were  found  at  around 2976  and  2875  cm−1. A  characteristic band  for 
secondary  amines  identified  at  3180  cm−1  was  confirmed  in  the  IR  spectra  of  the  complex. 
Coordination  through  the  nitrogen  atom  can  be  supposed  on  the  basis  of  changes  in  values  of 
asymmetric C–N vibrations from 803 (ligand precursor) to 863 cm−1 for complex. 
In  1H NMR  spectra,  the  hydrogen  atoms  belonging  to  the  secondary  amino  groups  of  the 
complex appeared at around 5.2 ppm (compared to the ligand precursor, approximately 10 ppm). 
The  resonances  of  ethylene  hydrogen  atoms  (C1H2)  showed  coordination‐induced  shifts  (ca.  0.4 




the  ligand precursor  [25]. Two  sets of  signals were  found  for  the  synthesized gold(III)  complex, 
indicating the formation of diastereoisomers arising out of new nitrogen stereocenters formed due to 
coordination.  This  is  also  confirmed with H,H‐COSY NMR  spectroscopy. Moreover, H,H‐COSY 
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a 1736 cm−1, similarly to the ligand precursor [(S,S)-H2Et2eddl]Cl2 [25], indicating that coordination
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resonances of ethylene hydrogen atoms (C1H2) showed coordination-induce shifts (ca. 0.4 ppm),
which also indicated that coordination occurred via nitrogen atoms. In the 13C NMR spectrum,
carbonyl atoms show resonances at expected chemical shifts for this class of compounds where oxygen
is not participati g in coordination (C3, 169 ppm) [33,34]. The resonances of carbon at ms from
the ethylenediamine moiety (C1) in the complex is shifted downfiel relative to that of the ligand
pr cursor [25]. Two sets of signals were found for the synthesized gold(III) complex, indicating the
form tion of diastereoisomers arising ut of new itrogen stereocenters formed due to coordination.
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This is also confirmed with H,H-COSY NMR spectroscopy. Moreover, H,H-COSY NMR spectroscopy
excluded the presence of a (R,S)-N,N′-isomer. Thus, for this diastereoisomer, two resonances expected
are for the chiral CH as well as for NH hydrogen atoms, which were not detected. However, NMR
spectroscopy could not provide strong evidence for (R,R)-N,N′ and (S,S)-N,N′ isomers assignment,
because of the absence of well-defined resonances in 1H and a similar correlation pattern in the
H,H-NOESY spectrum.
3.2. Quantum Chemical Calculations
Quantum chemical calculations of similar gold(III) complexes have been performed and reported
before [19,20]. Herein, density functional theory (DFT) calculations were used to estimate the most
energetically-favorable isomers obtained for the [AuCl2{(S,S)-Et2eddl}]PF6 complex. The calculated
results for [AuCl2{(S,S)-Et2eddl}]PF6 showed that the (R,R)-N,N′ diastereoisomer is the most stable.
The difference in the total electronic energies between diastereoisomers (R,R)-N,N′ and (S,S)-N,N′ was
∆Etot = 2.71 kcal/mol. The energy of the third isomer, (R,S)≡(S,R) was 5.65 kcal/mol higher than
the energy of the (R,R) isomer. These results are in agreement with those obtained for platinum(IV)
complexes with the same type of ligands [35]. Due to a small difference in energy and as shown by
NMR spectroscopy, DFT also points out the formation of (R,R)-N,N′ and (S,S)-N,N′ diastereoisomers.




resonances  expected  are  for  the  chiral CH  as well  as  for NH  hydrogen  atoms, which were  not 




Quantum  chemical  calculations  of  similar  gold(III)  complexes  have  been  performed  and 
reported before [19,20]. Herein, density functional theory (DFT) calculations were used to estimate 
the most  energetically‐favorable  isomers  obtained  for  the  [AuCl2{(S,S)‐Et2eddl}]PF6  complex. The 












In  our  previous  research,  gold(III)  complexes with  various  (S,S)‐R2edda  type  ligands were 
examined  for  their  activities  as  anticancer  agents  [19,20].  In  this work,  the  cytotoxic potential of 
ligand  precursor,  [(S,S)‐H2Et2eddl]Cl2,  and  a  new  synthesized  gold(III)  complex 
[AuCl2{(S,S)‐Et2eddl}]PF6 were  studied  in  a  panel  of malignant  cell  lines,  originating  from  solid 
tumors as well as against a normal, non‐cancerous cell line. In Figure 2, graphs showing the survival 
of  HeLa,  LS174,  MCF7,  A549,  and  non‐cancerous  MRC‐5  cells  in  the  presence  of  different 
concentrations of  [(S,S)‐H2Et2eddl]Cl2 and  [AuCl2{(S,S)‐Et2eddl}]PF6 are presented. The  IC50 values 
for compounds against these cell lines are summarized in Table 1.   
The  results  indicate  that  ligand  precursor  and  complex  showed  very  good  to  moderate 
cytotoxic  activity  against  all  tested  malignant  cell  lines.  It  is  evident  that  ligand  precursor,   
[(S,S)‐H2Et2eddl]Cl2,  and  the  complex,  [AuCl2{(S,S)‐Et2eddl}]PF6,  showed  less  toxicity  than   




Figure 1. Calculated structures of complex [AuCl2{(S,S)-Et2eddl}]PF6. Only H atoms bonded to chiral
atoms are shown.
3.3. Biological Activity
In our previous research, gold(III) complexes with various (S,S)-R2edda type ligands were
exami ed for their activiti s as anticancer agents [19,20]. In this work, the cytotoxic potenti l of ligand
precursor, [(S,S)-H2Et2eddl]Cl2, and a new synthe ized gold(III) complex [AuCl2{(S,S)-Et2eddl}]PF6
were studied in a panel of malignant cell lines, originati g from solid tumors as well as against a
normal, non-cancerous cell line. In Figure 2, graphs showing the survival of HeLa, LS174, MCF7, A549,
and non-cancerous MRC-5 cells in the prese ce f different co centrations of [(S,S)-H2Et2eddl]Cl2 and
[AuCl2{(S,S)-Et2eddl}]PF6 are presented. The IC50 values for compounds against these cell lines are
summarized in Table 1.
The results indicate that ligand precur or and complex showed very good to moderate cytotoxic
activity against all tested malignant cell lin s. It is evident that ligand pr curso , [(S,S)-H2Et2ed l]Cl2,
and the complex, [AuCl2{(S,S)-Et2eddl}]PF6, showed les toxicity than the Na[AuCl4] complex.
Comparing the I 50 v lues, it is found that complex [AuCl2{(S,S)-Et2eddl}]PF6 shows a cytotoxicity
several times stronger than the ligand precursor and Na[AuCl4]. The most promising activity was
found for [AuCl2{(S,S)-Et2eddl}]PF6 against the LS174 cell line, which was five times higher than that
for cisplatin.
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HeLa  LS174  MCF7  A549  MRC5 
[(S,S)‐H2Et2eddl]Cl2  53.97 ± 2.72  53.23 ± 4.12  46.97 ± 2.19  38.44 ± 1.39  55.91 ± 0.61 
[AuCl2{(S,S)‐Et2eddl}]PF6  18.25 ± 0.87  7.44 ± 1.19  41.10 ± 1.96  36.35 ± 1.75  24.94 ± 0.43 
Na[AuCl4]  52.80 ± 2.93  39.89 ± 3.60  75.70 ± 0.38  45.66 ± 2.35  54.60 ± 3.11 
cisplatin  6.90 ± 1.71  22.40 ± 0.44  18.13 ± 0.57  17.20 ± 0.82  14.21 ± 1.54 
3.4. Selectivity Study 
Against  the  non‐cancerous  lung  fibroblasts  (MRC‐5),  tested  compounds were  found  to  be 
moderately sensitive to toxic. In the case of [AuCl2{(S,S)‐Et2eddl}]PF6, a selectivity greater than that 
for  cisplatin was  found  against LS174  cells. Additionally,  ligand precursor  is also more  selective 
against MCF7  cells  than  cisplatin. With  an  activity  three  times higher  against LS174  cells  and  a 




HeLa  LS174  MCF7  A549 
[(S,S)‐H2Et2eddl]Cl2  0.93 ± 0.04  1.05 ± 0.08  1.19 ± 0.06  1.45 ± 0.05 
[AuCl2{(S,S)‐Et2eddl}]PF6  1.37 ± 0.07  3.35 ± 0.54  0.61 ± 0.03  0.69 ± 0.04 
Na[AuCl4]  1.03 ± 0.08  1.37 ± 0.15  0.72 ± 0.04  1.20 ± 0.09 
cisplatin  2.06 ± 0.56  0.63 ± 0.07  0.78 ± 0.09  0.83 ± 0.10 
4. Conclusions   
The  synthesis  of  a  novel  gold(III)  complex  with  O,O’‐diethyl  ester  of 
ethylenediamine‐N,N’‐di‐2‐(4‐methyl)pentanoic acid is described. The compound was characterized 
Figure 2. The survival of HeLa, LS174, MCF7, A549, and MRC-5 cells incubated for 72 h with different
concentrations of investigated compounds (microculture tetrazolium test (MTT) assay).
Table 1. Concentrations of [(S,S)-H2Et2eddl]Cl2, [AuCl2{(S,S)-Et2eddl}]PF6, Na[AuCl4], and cisplatin




HeLa LS174 MCF7 A549 MRC5
[(S,S)-H2Et2eddl]Cl2 53.97 ± 2.72 53.23 ± 4.12 46.97 ± 2.19 38.44 ± 1.39 55.91 ± 0.61
[AuCl2{(S,S)-Et2eddl}]PF6 18.25 ± 0.87 7.44 ± 1.19 41.10 ± 1.96 36.35 ± 1.75 24.94 ± 0.43
Na[AuCl4] 52.80 ± 2.93 39.89 ± 3.60 75.70 ± 0.38 45.66 ± 2.35 54.60 ± 3.11
cisplatin 6.90 ± 1.71 22.40 ± 0.44 18.13 ± 0.57 17.20 ± 0.82 14.21 ± 1.54
3.4. Selectivity Study
Against the non-cancerous lung fibroblasts (MRC-5), tested compounds were found to be
moderately sensitive to toxic. In the case of [AuCl2{(S,S)-Et2eddl}]PF6, a selectivity greater than
that for cisplatin was found against LS174 cells. Additionally, ligand precursor is also more selective
against MCF7 cells than cisplatin. With an activity three times higher against LS174 cells and a
selectivity 3.5 times higher than cisplatin, complex [AuCl2{(S,S)-Et2eddl}]PF6 could be a promising
candidate for further stages of screening. Selectivity indices are given in Table 2.
Table 2. Selectivity indices.
Compounds
IC50 (MRC-5)/IC50 (cell line)
HeLa LS174 MCF7 A549
[(S,S)-H2Et2eddl]Cl2 0.93 ± 0.04 1.05 ± 0.08 1.19 ± 0.06 1.45 ± 0.05
[AuCl2{(S,S)-Et2eddl}]PF6 1.37 ± 0.07 3.35 ± 0.54 0.61 ± 0.03 0.69 ± 0.04
Na[AuCl4] 1.03 0.08 1.37 ± 0.15 0.72 ± 0.04 1.20 ± 0.09
cisplatin 2.06 ± 0.56 0.63 ± 0.07 0.78 ± 0.09 0.83 ± 0.10
4. Conclusions
The synthesis of a novel gold(III) complex with O,O′-diethyl ester of ethylenediamine-N,N′-
di-2-(4-methyl)pentanoic acid is described. The compound was characterized by IR, 1H, and 13C NMR
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spectroscopy, mass spectrometry, and elemental analysis. NMR spectroscopy showed the presence of
two (R,R)- and (S,S)-N,N′ diastereoisomers, and DFT calculations indicate the formation of the same
isomers. The newly synthesized complex [AuCl2{(S,S)-Et2eddl}]PF6, as well as corresponding ligand
precursor [(S,S)-H2Et2eddl]Cl2, were tested against tumor cell lines (HeLa, LS174, MCF7, and A549)
and the non-cancerous cell line human embryonic lung fibroblast (MRC-5) using the MTT assay.
The complex showed up to three times stronger cytotoxicity than the ligand precursor against HeLa
cells, and even up to seven times against LS174 cells (IC50 = 7.4 ± 1.2 µM), which is comparable to
cisplatin activity. Additionally, [AuCl2{(S,S)-Et2eddl}]PF6 showed 3.5 times higher selectivity in LS174
cells than cisplatin.
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